Bioheart Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bioheart Inc Announces US FDA Clinical Program Using Adipose Cells
Bioheart Inc announced that they will begin a US clinical program called the ANGEL trial utilizing adipose derived cells or LipiCell for congestive heart failure patients. Using the clinical data from a Phase I/II trial in Mexico and preclinical studies, Bioheart will apply to the FDA to begin a Phase I study in the US. In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, six congestive heart failure patients have been successfully treated in a Phase I/II trial at Hospital Angeles Tijuana. The therapy involves the use of stem cells derived from the patient's own fat (adipose tissue) obtained using liposuction. These patients have demonstrated on average, an absolute improvement of 13 percentage points in ejection fraction and an increase of 100 meters in their 6 minute walk distance.
Latest Developments for Bioheart Inc
Latest Key Developments in Biotechnology
- Bioxyne Ltd Announces Termination Of Proposed Acquisition Of Vitality Devices Pty Ltd
- Repros Therapeutics Inc Announces That FDA Recommends Running Phase 2b Trial Of Proellex-V In Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
- Norda ASA Plans Delisting from Oslo Stock Exchange
- Stemline Therapeutics Inc Announces Closing Of $60 Million Public Offering Of Common Stock
- Share this
- Digg this